Anzeige
Mehr »
Donnerstag, 30.10.2025 - Börsentäglich über 12.000 News
Die 80-Milliarden-Dollar-Nuklear-Renaissance: Warum Uran der heißeste Sektor der Welt ist
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40NWE | ISIN: US74638P2083 | Ticker-Symbol: 1YI
NASDAQ
29.10.25 | 20:59
1,055 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
PURPLE BIOTECH LTD ADR Chart 1 Jahr
5-Tage-Chart
PURPLE BIOTECH LTD ADR 5-Tage-Chart

Aktuelle News zur PURPLE BIOTECH Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiPurple Biotech: Aktie steigt um 102 % nach Meilenstein in der Antikörper-Produktion3
MiPurple Biotech stock soars after manufacturing milestone for tri-specific antibody1
MiPurple Biotech Ltd.: Purple Biotech Achieves Manufacturing Milestone for IM1240, a Tri-Specific Antibody from the CAPTN-3 Platform137Achieved commercially viable yield for IM1240, positioning the program competitively for future development Validates scalability of the CAPTN-3 tri-specific antibody platform IM1240, the first CAPTN-3...
► Artikel lesen
DiPURPLE BIOTECH LTD. - 6-K, Report of foreign issuer2
20.10.Purple Biotech announces receipt of Nasdaq minimum bid price notification3
20.10.Purple Biotech Ltd.: Purple Biotech Announces Receipt of Nasdaq Minimum Bid Price Notification91REHOVOT, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek...
► Artikel lesen
19.09.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer3
10.09.Purple Biotech Ltd.: Purple Biotech Receives Intention to Grant a European Patent Covering NT219 Combinations with Immunotherapies or MEK Inhibitors to Overcome Tumor Resistance16
PURPLE BIOTECH Aktie jetzt für 0€ handeln
10.09.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer1
05.09.Purple Biotech Ltd.: Purple Biotech Announces Closing of Up To $18 Million Public Offering $6 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants5
04.09.Purple Biotech prices $6M public offering, $12M potential via warrants; shares down7
04.09.Purple Biotech Ltd.: Purple Biotech Announces Pricing of Up To $18 Million Public Offering2
03.09.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer1
29.08.PURPLE BIOTECH LTD. - F-1, Registration statement for certain foreign private issuers4
06.08.Purple Biotech Ltd. Q2 Profit Drops1
06.08.Purple Biotech Ltd.: Purple Biotech Reports Second Quarter 2025 Financial Results156Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG2A, and tumor-associated antigen arms...
► Artikel lesen
06.08.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer1
23.07.Purple Biotech Ltd.: Purple Biotech CEO Issues Letter to Shareholders Highlighting Pipeline Progress and Clinical Milestones Achieved in First Half of 2025222REHOVOT, Israel, July 23, 2025 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that seek...
► Artikel lesen
23.07.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer1
10.07.PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer2
Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1